IDT Australia Ltd
ASX:IDT
IDT Australia Ltd
ASX:IDT
Price:
0.096 AUD
-3.03%
Market Closed
Updated:
May 20, 2024
IDT Australia Ltd
Cost of Revenue
|
IDT Australia Ltd
Cost of Revenue Peer Comparison
Comparables:
MYX
NEU
BOT
PBP
C
CU6
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
IDT Australia Ltd
ASX:IDT
|
Cost of Revenue
-AU$2.4m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cost of Revenue
-AU$99.9m
|
CAGR 3-Years
26%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Probiotec Ltd
ASX:PBP
|
Cost of Revenue
-AU$155m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-15%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is IDT Australia Ltd's Cost of Revenue?
Cost of Revenue
-2.4m
AUD
-2.4m
AUD
Based on the financial report for Dec 31, 2023, IDT Australia Ltd's Cost of Revenue amounts to -2.4m AUD.
What is IDT Australia Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
4%
4%
Over the last year, the Cost of Revenue growth was -19%. The average annual Cost of Revenue growth rates for IDT Australia Ltd have been -17% over the past three years , 1% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet
